Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment
- PMID: 38007408
- DOI: 10.1007/s00415-023-12102-5
Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment
Abstract
Background: Available criteria for cognitive phenotypes in multiple sclerosis (MS) do not consider the severity of impairment.
Objectives: To identify cognitive phenotypes with varying degrees of impairment in MS patients and describe their demographic, clinical and MRI characteristics.
Methods: Two hundred and forty-three MS patients and 158 healthy controls underwent neuropsychological tests to assess memory, attention, and executive function. For each domain, mild impairment was defined as performing 1.5 standard deviations below the normative mean on two tests, while the threshold for significant impairment was 2 standard deviations. Patients were classified into cognitive phenotypes based on severity of the impairment (mild/significant) and number of domains affected (one/more).
Results: Five cognitive phenotypes emerged: Preserved cognition (PC; 56%), Mild Single-Domain Impairment (MSD; 15%), Mild Multi-Domain Impairment (MMD; 9%), Significant Single-Domain Impairment (SSD; 12%), Significant Multi-Domain Impairment (SMD; 8%). Compared with PC, MSD patients were older, had longer disease duration (DD) and higher T2-hyperintense lesion volume (LV; all p ≤ 0.02); MMD patients were older, had longer DD, higher disability, higher T2 LV and lower thalamic volume (all p ≤ 0.01); SSD patients had longer DD and lower gray matter cortical volume, thalamic, caudate, putamen and accumbens volumes (all p ≤ 0.04); and SMD patients were older, had longer DD, higher disability and more extensive structural damage in all brain regions explored (all p ≤ 0.03), except white matter and amygdala volumes.
Conclusions: We identified five cognitive phenotypes with graded levels of impairment. These phenotypes were characterized by distinct demographic, clinical and MRI features, indicating potential variations in the neural substrates of dysfunction throughout disease stages.
Keywords: Cognitive dysfunction; Cognitive phenotypes; Magnetic resonance imaging; Multiple sclerosis.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
References
-
- Rocca MA, Amato MP, De Stefano N, Enzinger C, Geurts JJ, Penner IK, Rovira A et al (2015) Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 14(3):302–317. https://doi.org/10.1016/S1474-4422(14)70250-9 - DOI - PubMed
-
- Amato MP, Portaccio E, Goretti B, Zipoli V, Hakiki B, Giannini M, Pastò L et al (2010) Cognitive impairment in early stages of multiple sclerosis. Neurol Sci 31(S2):211–214. https://doi.org/10.1007/s10072-010-0376-4 - DOI
-
- Benedict RHB, Amato MP, DeLuca J, Geurts JJG (2020) Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol 19(10):860–871. https://doi.org/10.1016/s1474-4422(20)30277-5 - DOI - PubMed - PMC
-
- Marchesi O, Bonacchi R, Valsasina P, Preziosa P, Pagani E, Cacciaguerra L, Meani A et al (2021) Functional and structural MRI correlates of executive functions in multiple sclerosis. Mult Scler J 28(5):742–756. https://doi.org/10.1177/13524585211033184 - DOI
-
- Chalah MA, Ayache SS (2017) Deficits in social cognition: an unveiled signature of multiple sclerosis. J Int Neuropsychol Soc 23(3):266–286. https://doi.org/10.1017/s1355617716001156 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
